- How much cash does CLDX have?
- Celldex Therapeutics, Inc. (CLDX)'s cash and short-term investments balance is $451.5 million as of the quarter ended March 31, 2026. The Cash on Hand card on this page shows the quarter-by-quarter trend and breakdown by cash equivalents vs short-term securities.
- What is CLDX's total debt?
- Celldex Therapeutics, Inc.'s most recent total debt — long-term plus short-term obligations — is $1.9 million; net debt (debt minus cash) is $-449.6 million. The Net Debt card on this page tracks the trend over time, revealing deleveraging or leveraging cycles.
- What is CLDX's debt-to-equity ratio?
- Celldex Therapeutics, Inc. (CLDX)'s debt-to-equity is calculated from total liabilities divided by shareholders' equity and is shown alongside other leverage metrics. Higher ratios indicate more aggressive use of debt financing.
- How many shares of CLDX are outstanding?
- Celldex Therapeutics, Inc. has approximately 66.6 million basic weighted-average shares outstanding as of the quarter ended March 31, 2026. The Shares card on this page shows the trend — whether the company is issuing new shares (dilution) or buying back shares (concentration).
- How current is CLDX's balance sheet data?
- Celldex Therapeutics, Inc. (CLDX)'s balance-sheet figures on this page are as of the quarter ended March 31, 2026 — the most recently filed period. Cash, debt, and share-count balances refresh as each new 10-Q and 10-K is parsed, typically within 48 hours of SEC submission.
